|
ホンダ ゴロウ
HONDA Gorou
本田 五郎 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervised by the Japanese Society of Hepato-Biliary-Pancreatic Surgery |
| 掲載誌名 | 正式名：Journal of hepato-biliary-pancreatic sciences 略 称：J Hepatobiliary Pancreat Sci ISSNコード：18686982/18686974 |
| 掲載区分 | 国内 |
| 巻・号・頁 | 32(1),pp.69-81 |
| 著者・共著者 | ARIAKE Kyohei, MIZUMA Masamichi, UNNO Michiaki, SATOI Sohei, YAMAMOTO Naoto, HAYASHI Masamichi, KAWAI Manabu, AKITA Hirofumi, TOYODA Eiji, FUJII Tsutomu, SASAKI Masaru, HAKAMADA Kenichi, WATANABE Jota, HATANO Etsuro, HODAKA Masaaki, HORANO Satoshi, KURAHARA Hiroshi, MATSUMOTO Ippei, HONDA Goro, OGURA Toshiro, NAKAMURA Masafumi, ENDO Itaru |
| 発行年月 | 2025/01 |
| 概要 | BACKGROUND:The aim of this study was to determine the optimal treatment for patients with pancreatic cancer (PaCa) having positive peritoneal cytology (PPC).METHODS:This multicenter retrospective study included patients with PPC treated at 78 high-volume centers between January 2012 and December 2020. Prognoses after resection (S-group) and initiation of nonsurgical treatment (N-group) were compared. Prognostic factors for survival in both groups were analyzed. Detailed characteristics of conversion surgery (CS) in the N-group were evaluated.RESULTS:In total, 568 enrolled patients were classified into an S-group (n = 445) or an N-group (n = 123). Median survival times (MSTs) were 19.0 months and 19.3 months, respectively, with no significant difference in prognosis (p = .845). The intervenable prognostic factors for survival were adjuvant treatment in the S-group (p < .001) and CS in the N-group (p < .001). Following CS, the MST was prolonged to 45.6 months, and peritoneal or liver recurrence decreased considerably. CS can be expected if PPC is diagnosed before neoadjuvant treatment and when combination treatment is initiated.CONCLUSION:Surgical resection may not be beneficial for improving survival when PPC is evident. Chemotherapy aiming for CS may be the optimal treatment for such patients. |
| DOI | 10.1002/jhbp.12074 |
| PMID | 39317950 |